Burning Rock Biotech (NASDAQ:BNR) Shares Down 3.7% – Should You Sell?

Posted by Brian Himes on Aug 14th, 2026

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR – Get Free Report)’s stock price fell 3.7% during trading on Thursday . The company traded as low as $9.29 and last traded at $9.5580. Approximately 2,971 shares were traded during trading, a decline of 54% from the average session volume of 6,448 shares. The stock had previously closed at $9.93.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BNR shares. Wall Street Zen lowered Burning Rock Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings cut Burning Rock Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on BNR

Burning Rock Biotech Trading Down 3.7%

The company has a market cap of $100.55 million, a P/E ratio of -11.66 and a beta of 1.34. The firm’s 50 day moving average is $9.15 and its two-hundred day moving average is $16.95. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR – Get Free Report) last released its earnings results on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.29) by $2.09. The business had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Insider Activity

In other Burning Rock Biotech news, Director Yusheng Han bought 24,900 shares of Burning Rock Biotech stock in a transaction dated Friday, June 26th. The stock was bought at an average cost of $8.00 per share, with a total value of $199,200.00. Following the completion of the acquisition, the director directly owned 18,404,086 shares in the company, valued at approximately $147,232,688. The trade was a 0.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have acquired 731,410 shares of company stock valued at $6,182,660. Corporate insiders own 30.30% of the company’s stock.

Institutional Trading of Burning Rock Biotech

A number of institutional investors have recently modified their holdings of BNR. Marshall Wace LLP purchased a new stake in Burning Rock Biotech during the 4th quarter worth about $220,000. Renaissance Technologies LLC grew its holdings in Burning Rock Biotech by 13.8% during the 1st quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares in the last quarter. Prospera Financial Services Inc grew its holdings in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares in the last quarter. Finally, Crcm LP increased its position in shares of Burning Rock Biotech by 121.8% during the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock valued at $9,902,000 after buying an additional 269,851 shares during the period. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.